Drug Concentration in Rat Plasma, Bladder, and Prostate after Mirodenafil Administration in a Chronic Pelvic Ischemia Model

Ji Sung Shim, Jae Hyun Bae

Research output: Contribution to journalArticle

Abstract

Objective To evaluate the distribution of a daily phosphodiesterase type 5 inhibitor dose (mirodenafil) in rat plasma and bladder and prostate tissue in a model of atherosclerosis-induced chronic pelvic ischemia. Methods Thirty-two 18-week-old male Sprague Dawley rats were divided into two groups. Group I (n = 16) comprised a chronic pelvic ischemia model treated with mirodenafil and group II (n = 16) comprised a sham-operated model also treated with mirodenafil. The mirodenafil concentrations in each organ were measured at specific time points after 14 days of daily mirodenafil administration. The drug distribution ratio of group I to group II of each organ was measured, and the bladder tissue-to-plasma and prostate tissue-to-plasma ratios were calculated. Results The mean drug concentration in the bladder of the rats in group I did not differ significantly from that of group II after mirodenafil administration. In the prostate, the mean drug concentration of group I was significantly higher than that of group II at 1 and 4 hours after drug administration. The drug concentration was higher in the bladder tissue than in the prostate tissue and the bladder tissue-to-plasma ratio was significantly higher than the prostate tissue-to-plasma ratio. Conclusion Our results suggest that mirodenafil levels might be sufficient in the target tissue after daily treatment in an ischemia-induced aging model. Considering the difficulties of tissue distribution study in human subjects, the results of this investigation provided meaningful evidence of the application of daily doses of mirodenafil for treating lower urinary tract symptoms in an aging population.

Original languageEnglish
Pages (from-to)244e1-244e5
JournalUrology
Volume91
DOIs
Publication statusPublished - 2016 May 1

Fingerprint

Prostate
Urinary Bladder
Ischemia
Pharmaceutical Preparations
Phosphodiesterase 5 Inhibitors
Lower Urinary Tract Symptoms
mirodenafil
Tissue Distribution
Sprague Dawley Rats
Atherosclerosis
Population

ASJC Scopus subject areas

  • Urology

Cite this

Drug Concentration in Rat Plasma, Bladder, and Prostate after Mirodenafil Administration in a Chronic Pelvic Ischemia Model. / Shim, Ji Sung; Bae, Jae Hyun.

In: Urology, Vol. 91, 01.05.2016, p. 244e1-244e5.

Research output: Contribution to journalArticle

@article{6b6b8098a11243099782a7dcad75203a,
title = "Drug Concentration in Rat Plasma, Bladder, and Prostate after Mirodenafil Administration in a Chronic Pelvic Ischemia Model",
abstract = "Objective To evaluate the distribution of a daily phosphodiesterase type 5 inhibitor dose (mirodenafil) in rat plasma and bladder and prostate tissue in a model of atherosclerosis-induced chronic pelvic ischemia. Methods Thirty-two 18-week-old male Sprague Dawley rats were divided into two groups. Group I (n = 16) comprised a chronic pelvic ischemia model treated with mirodenafil and group II (n = 16) comprised a sham-operated model also treated with mirodenafil. The mirodenafil concentrations in each organ were measured at specific time points after 14 days of daily mirodenafil administration. The drug distribution ratio of group I to group II of each organ was measured, and the bladder tissue-to-plasma and prostate tissue-to-plasma ratios were calculated. Results The mean drug concentration in the bladder of the rats in group I did not differ significantly from that of group II after mirodenafil administration. In the prostate, the mean drug concentration of group I was significantly higher than that of group II at 1 and 4 hours after drug administration. The drug concentration was higher in the bladder tissue than in the prostate tissue and the bladder tissue-to-plasma ratio was significantly higher than the prostate tissue-to-plasma ratio. Conclusion Our results suggest that mirodenafil levels might be sufficient in the target tissue after daily treatment in an ischemia-induced aging model. Considering the difficulties of tissue distribution study in human subjects, the results of this investigation provided meaningful evidence of the application of daily doses of mirodenafil for treating lower urinary tract symptoms in an aging population.",
author = "Shim, {Ji Sung} and Bae, {Jae Hyun}",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.urology.2016.02.017",
language = "English",
volume = "91",
pages = "244e1--244e5",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Drug Concentration in Rat Plasma, Bladder, and Prostate after Mirodenafil Administration in a Chronic Pelvic Ischemia Model

AU - Shim, Ji Sung

AU - Bae, Jae Hyun

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Objective To evaluate the distribution of a daily phosphodiesterase type 5 inhibitor dose (mirodenafil) in rat plasma and bladder and prostate tissue in a model of atherosclerosis-induced chronic pelvic ischemia. Methods Thirty-two 18-week-old male Sprague Dawley rats were divided into two groups. Group I (n = 16) comprised a chronic pelvic ischemia model treated with mirodenafil and group II (n = 16) comprised a sham-operated model also treated with mirodenafil. The mirodenafil concentrations in each organ were measured at specific time points after 14 days of daily mirodenafil administration. The drug distribution ratio of group I to group II of each organ was measured, and the bladder tissue-to-plasma and prostate tissue-to-plasma ratios were calculated. Results The mean drug concentration in the bladder of the rats in group I did not differ significantly from that of group II after mirodenafil administration. In the prostate, the mean drug concentration of group I was significantly higher than that of group II at 1 and 4 hours after drug administration. The drug concentration was higher in the bladder tissue than in the prostate tissue and the bladder tissue-to-plasma ratio was significantly higher than the prostate tissue-to-plasma ratio. Conclusion Our results suggest that mirodenafil levels might be sufficient in the target tissue after daily treatment in an ischemia-induced aging model. Considering the difficulties of tissue distribution study in human subjects, the results of this investigation provided meaningful evidence of the application of daily doses of mirodenafil for treating lower urinary tract symptoms in an aging population.

AB - Objective To evaluate the distribution of a daily phosphodiesterase type 5 inhibitor dose (mirodenafil) in rat plasma and bladder and prostate tissue in a model of atherosclerosis-induced chronic pelvic ischemia. Methods Thirty-two 18-week-old male Sprague Dawley rats were divided into two groups. Group I (n = 16) comprised a chronic pelvic ischemia model treated with mirodenafil and group II (n = 16) comprised a sham-operated model also treated with mirodenafil. The mirodenafil concentrations in each organ were measured at specific time points after 14 days of daily mirodenafil administration. The drug distribution ratio of group I to group II of each organ was measured, and the bladder tissue-to-plasma and prostate tissue-to-plasma ratios were calculated. Results The mean drug concentration in the bladder of the rats in group I did not differ significantly from that of group II after mirodenafil administration. In the prostate, the mean drug concentration of group I was significantly higher than that of group II at 1 and 4 hours after drug administration. The drug concentration was higher in the bladder tissue than in the prostate tissue and the bladder tissue-to-plasma ratio was significantly higher than the prostate tissue-to-plasma ratio. Conclusion Our results suggest that mirodenafil levels might be sufficient in the target tissue after daily treatment in an ischemia-induced aging model. Considering the difficulties of tissue distribution study in human subjects, the results of this investigation provided meaningful evidence of the application of daily doses of mirodenafil for treating lower urinary tract symptoms in an aging population.

UR - http://www.scopus.com/inward/record.url?scp=84962107042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962107042&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2016.02.017

DO - 10.1016/j.urology.2016.02.017

M3 - Article

C2 - 26919966

AN - SCOPUS:84962107042

VL - 91

SP - 244e1-244e5

JO - Urology

JF - Urology

SN - 0090-4295

ER -